Trial Profile

A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018+Standard Chemotherapy and IN10018+Standard Chemotherapy+KN046 in Subjects With Advanced Pancreatic Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erfonrilimab (Primary) ; Gemcitabine (Primary) ; Ifebemtinib (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Adenosquamous carcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors InxMed

30 Apr 2025 Planned End Date changed from 1 Mar 2026 to 31 Mar 2026.
30 Apr 2025 Planned primary completion date changed from 1 Dec 2025 to 31 Dec 2025.
27 Apr 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com